Abstract
It has been recently shown that in vitro platelet aggregation is inhibited when platelet concentration in platelet-rich plasma (PRP) is "normalized" by the addition of platelet-poor plasma (PPP). In this study we tested the hypothesis that the large amount of PPP required to "normalize" PRP in patients with thrombocytosis may result in falsely defective platelet function. To this end, we evaluated platelet aggregation in PRP samples "normalized" with either PPP or buffer in 16 patients with high platelet counts induced by myeloproliferative disorders. Comparison with the results obtained in healthy subjects demonstrated that patients had reduced platelet responses to ADP or collagen in PRP/PPP samples, but normal responses in PRP/buffer. By contrast, the majority of patients had severely defective platelet response to epinephrine independently from the methodological approach. We suggest that the reduced in vitro platelet aggregation previously described in patients with myeloproliferative disorders and thrombocytosis partially derived from a laboratory artefact.
| Original language | English |
|---|---|
| Pages (from-to) | 131-134 |
| Number of pages | 4 |
| Journal | Platelets |
| Volume | 20 |
| Issue number | 2 |
| DOIs | |
| Publication status | Published - Mar 2009 |
Fingerprint
Keywords
- Laboratory artefact
- Myeloproliferative disorders
- Platelet aggregation
- Thrombosis
ASJC Scopus subject areas
- Hematology
Cite this
In vitro platelet aggregation defects in patients with myeloproliferative disorders and high platelet counts : Are they laboratory artefacts? / Grignani, Claudio; Noris, Patrizia; Tinelli, Carmine; Barosi, Giovanni; Balduini, Carlo L.
In: Platelets, Vol. 20, No. 2, 03.2009, p. 131-134.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - In vitro platelet aggregation defects in patients with myeloproliferative disorders and high platelet counts
T2 - Are they laboratory artefacts?
AU - Grignani, Claudio
AU - Noris, Patrizia
AU - Tinelli, Carmine
AU - Barosi, Giovanni
AU - Balduini, Carlo L.
PY - 2009/3
Y1 - 2009/3
N2 - It has been recently shown that in vitro platelet aggregation is inhibited when platelet concentration in platelet-rich plasma (PRP) is "normalized" by the addition of platelet-poor plasma (PPP). In this study we tested the hypothesis that the large amount of PPP required to "normalize" PRP in patients with thrombocytosis may result in falsely defective platelet function. To this end, we evaluated platelet aggregation in PRP samples "normalized" with either PPP or buffer in 16 patients with high platelet counts induced by myeloproliferative disorders. Comparison with the results obtained in healthy subjects demonstrated that patients had reduced platelet responses to ADP or collagen in PRP/PPP samples, but normal responses in PRP/buffer. By contrast, the majority of patients had severely defective platelet response to epinephrine independently from the methodological approach. We suggest that the reduced in vitro platelet aggregation previously described in patients with myeloproliferative disorders and thrombocytosis partially derived from a laboratory artefact.
AB - It has been recently shown that in vitro platelet aggregation is inhibited when platelet concentration in platelet-rich plasma (PRP) is "normalized" by the addition of platelet-poor plasma (PPP). In this study we tested the hypothesis that the large amount of PPP required to "normalize" PRP in patients with thrombocytosis may result in falsely defective platelet function. To this end, we evaluated platelet aggregation in PRP samples "normalized" with either PPP or buffer in 16 patients with high platelet counts induced by myeloproliferative disorders. Comparison with the results obtained in healthy subjects demonstrated that patients had reduced platelet responses to ADP or collagen in PRP/PPP samples, but normal responses in PRP/buffer. By contrast, the majority of patients had severely defective platelet response to epinephrine independently from the methodological approach. We suggest that the reduced in vitro platelet aggregation previously described in patients with myeloproliferative disorders and thrombocytosis partially derived from a laboratory artefact.
KW - Laboratory artefact
KW - Myeloproliferative disorders
KW - Platelet aggregation
KW - Thrombosis
UR - http://www.scopus.com/inward/record.url?scp=61649084981&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=61649084981&partnerID=8YFLogxK
U2 - 10.1080/09537100802691544
DO - 10.1080/09537100802691544
M3 - Article
C2 - 19235056
AN - SCOPUS:61649084981
VL - 20
SP - 131
EP - 134
JO - Platelets
JF - Platelets
SN - 0953-7104
IS - 2
ER -